vibration training approach in liver cirrhosis

Conditions: Liver Cirrhosis

Summary: * comprehensive investigation of the impact of side-alternating whole-body vibration training on muscle mass and muscle strength in patients with liver cirrhosis and sarcopenia * simultaneous characterization and evaluation of dynamic changes in health-related quality of life in our patient cohort with liver cirrhosis and sarcopenia through side-alternating whole-body vibration training.


Eligibility criteria:
inclusion criteria: * patients with confirmed or newly diagnosed compensated liver cirrhosis suffering from sarcopenia (combined decrease in muscle mass and muscle strength) * the liver cirrhosis is in a compensated stage. * the following etiologies of chronic liver disease are present: chronic hepatitis b infection, chronic hepatitis c infection, alcoholic liver disease, autoimmune hepatitis, cholestatic liver disease (pbc, psc), or other chronic hepatopathy. * alcohol abstinence of at least 3 months in cases of alcohol-related liver disease. * routine cancer screening for the presence of a liver tumor (hcc surveillance) is routinely performed using mri or ct scans, as ultrasound assessment is severely limited. * permission from the treating physician to engage in physical activity. * signed informed consent form. exclusion criteria: * non-compliance with inclusion criteria * patients with recent hospitalizations (within the last 3 months) due to gastrointestinal bleeding, hepatic encephalopathy, or spontaneous bacterial peritonitis * presence of inadequately treated portal hypertension * known chronic liver disease not described in the above groups * alcohol consumption \>20 g per day * excessive alcohol consumption during the study period leads to exclusion from the study * substance abuse * taking medications known to affect muscle mass or strength (e.g., amiodarone, chloroquine, macrolides) * taking medications known to cause movement disorders (e.g., reserpine, lithium, cyclosporine a, dopamine agonists) * patients with unstable cardiovascular diseases: e.g., unstable angina pectoris, uncontrolled hypertension (≥ 160/100 mmhg), uncontrolled diabetes (blood sugar \> 250 mg/dl), history of myocardial infarction or stroke * patients with musculoskeletal deformities, symptomatic rheumatoid or osteoarthritis * patients with untreated or newly diagnosed active malignant tumors in history * patients with neuromuscular or neurodegenerative diseases * patients with untreated hernias * patients with symptomatic, known untreated aortic aneurysm, with recent hospitalizations (within the last 6 months) * patients with fractures within the last 12 months * participation in moderate-intensity training programs for more than 2 hours per week * patients who have received chemotherapy at the time of the study or in the past 3 months * other underlying conditions that contraindicate vibration training and/or functional performance tests * circumstances preventing the individual from assessing the nature, scope, and possible consequences of the clinical trial * signs indicating that the subject is likely not to adhere to the study protocol (e.g., lack of cooperation) a. definition of hepatic decompensation * occurrence of symptomatic ascites, hepatic encephalopathy, portal hypertensive bleeding (e.g., esophageal variceal bleeding), infection

Keywords: sarcopenia